Urology Times staff

Welcome to another installment of Uranimals, our video series featuring urologists and their pets.

“We…had 1 of the largest African American hereditary prostate cancer projects funded through the National Cancer Institute,” says Curtis A. Pettaway, MD.

“In non–muscle-invasive bladder cancer, we need more biomarkers, something that can hopefully reduce the frequency of invasive procedures for these patients,” says Kristen Scarpato, MD, MPH.

“We do have a long way to go across the United States,” says Scott E. Eggener, MD.

“The root cause, I think, of most of the problems is a severe erosion of the patient-physician relationship,” William Lynes, MD.

“There was a point when people thought a trial [would] not be necessary because the answers [were] so clear cut. But obviously, more than just 1 person feels that these are not so clear-cut answers,” says Badar M. Mian, MD, FACS.

Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the roles of newer tests such as 18F-fluciclovine and 68Ga-PSMA-11.

Ulka Nitin Vaishampayan, MBBS, discusses the latest developments in the second-line setting in urothelial carcinoma.

Marijo Bilusic, MD, PhD, discusses research with the diabetes drug metformin in patients with prostate cancer.

“We’re [going to] have a whole new era of immune therapies and different novel ways to treat [patients], and then [utilize] combinations of these therapies,” says Michael S. Cookson, MD, MMHC, FACS.

“If you're thinking about urology, then what I would do is get exposure as early as possible,” says Curtis A. Pettaway, MD.

“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.

“In addition to having a well-rounded urology residency experience, where you're gaining surgical exposure to all the different aspects of urology, I think it's really important to add on and delve into a fellowship in gender affirming surgery,” says Geolani Dy, MD.

“Physicians should take better care of their own personal needs [and] create some boundaries…for a more balanced life,” says William Lynes, MD.

“I believe we are getting to an era where we will be able to cure a significant subset of patients who we are not able to cure today,” says Neil H. Bander, MD.

“One center would report 0.5% infection after transrectal. Another colleague may report 10%. That's a huge gap. And we have to understand why that gap is. The only way to find out will be through these randomized, controlled trials,” says Badar M. Mian, MD, FACS.

"The problem is that we are not very good at predicting who is not harboring any cancer in their bladder,” says Alexander Kutikov, MD, FACS.

“The decrease of frequency in doing these procedures may not put improving the techniques of the procedure at the forefront of the surgeon's mind,” says Svetlana Avulova, MD.

“I think that for the urologist, a lot of what we do in practice is very much appropriate for telemedicine,” says Kara L. Watts, MD.

“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.

“As president of SUO, it's really rewarding to be able to hand these giants these great awards,” says Michael S. Cookson, MD, MMHC, FACS.

“We should really try to adapt, know what we're doing to the specific patient based on their risk factors, prepare them appropriately, and understand that it's a dangerous complication. We should do everything we can to prevent it,” says Naeem Bhojani, MD, FRCSC.

“Take care of yourself, so we can take care of other people,” says Diana Londoño, MD.

“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.

“There is a whole range of ways in which urologists are involved in gender-affirming care,” says Geolani Dy, MD.

After the initial revolutionary breakthrough of sipuleucel-T (Provenge), the immunotherapy experience in prostate cancer has been challenging.

“Seeing the social media chatter, I think there is tremendous support for walking this back,” says Alexander Kutikov, MD, FACS.

“The most notable finding unquestionably was that peripheral nerve blocks have the ability to significantly reduce opioid requirements without compromising any pain control,” says Jared S. Winoker, MD.

“Men who experience biochemical recurrence after radical prostatectomy or radiation therapy should undergo PET scanning so that they can have specific targeted treatments administered to the site or sites of recurrence rather than [be treated] using the historical type of clinical parameters that we used in the past,” says Gerald L. Andriole, MD.

“We really have a pretty good understanding of the genomic landscape at the DNA/RNA level, both in non–muscle-invasive disease and muscle-invasive and metastatic disease,” says Seth P. Lerner, MD, FACS.